​In a securities class action, a “Lead Plaintiff motion” is a motion filed with the court which sets forth arguments as to why you should be appointed as lead plaintiff, who is responsible for hiring class counsel and litigating the case on behalf of the other class members. 

​Under the Private Securities Litigation Reform Act of 1995 (“PSLRA) any investor who purchased and suffered losses in securities during the class period in the case, seek appointment as lead plaintiff the securities class action lawsuit. Under the PSLRA, after a complaint is filed, a plaintiff has no later than 20 days to circulate notice to shareholders about the filing of the complaint notifying shareholders that “not later than 60 days after the date on which the notice is published, any member of the purported class may move the court to serve as lead plaintiff of the purported class.” 15 U.S. Code § 78u–4(a)(3)(A)(i)-(iii.).  

A lead plaintiff is generally the movant with the greatest financial interest in the relief sought by the putative class who is also typical and adequate of the putative class.  15 U.S. Code § 78u–4(a)(3)(B)(iii)(I)(bb)-(cc). A lead plaintiff is a fiduciary and acts on behalf of all other class members in directing the class action lawsuit.  The lead plaintiff can select a law firm of its choice to litigate the class action lawsuit. 
An investor’s ability to share in any potential future recovery of the class action lawsuit is not dependent upon serving as lead plaintiff. 

​If you were the victim of securities fraud, or would like to know more about the PSLRA’s lead plaintiff provisions, or have further questions, contact Stock Loss Lawyer Timothy L. Miles today.

The Fulgent Genetics class action lawsuit seeks to represent purchasers or acquirers of Fulgent Genetics, Inc. (NASDAQ: FLGT) securities between March 22, 2019 and August 4, 2022, inclusive (the “Class Period”).  The Fulgent Genetics class action lawsuit – captioned Pugley v. Fulgent Genetics, Inc., No. 22-cv-06764 (C.D. Cal.) – charges Fulgent Genetics and certain of its top executives with violations of the Securities Exchange Act of 1934.
​
If you suffered losses in Fulgent Genetics stock and wish to serve as lead plaintiff of the Fulgent Genetics class action lawsuit, please provide your information below.  You can also contact Fulgent Genetics Stock Loss Lawyer Timothy L. Miles by calling 855/846-6529 or via e-mail at tmiles@timmileslaw.com.  Lead plaintiff motions for the Fulgent Genetics class action lawsuit must be filed with the court no later than November 21, 2022. If you suffered losses in Fulgent Genetics stock and have questions, please contact Fulgent Genetics Stock Loss Lawyer Timothy L. Miles today.

​Fulgent Genetics provides COVID-19, molecular diagnostic, and genetic testing services to physicians and patients.  Fulgent Genetics must comply with the federal Anti-Kickback Statute, which prohibits the knowing and willful payment of “remuneration” to induce or reward patient referrals or the generation of business involving any item or service payable by the federal health care programs, as well as the federal Stark Law, which prohibits a physician from making referrals for certain designated health services, including laboratory services, that are covered by the Medicare program, to an entity with which the physician or an immediate family member has a direct or indirect financial relationship.
​
The Fulgent Genetics class action lawsuit alleges that defendants failed to disclose that: (i) Fulgent Genetics had been conducting medically unnecessary laboratory testing, engaging in improper billing practices in relation to laboratory testing, and providing or receiving remuneration in violation of the Anti-Kickback Statute and Stark Law; (ii) accordingly, Fulgent Genetics was likely to become subject to enhanced legal and regulatory scrutiny; (iii) Fulgent Genetics’ revenues, to the extent they were derived from the foregoing unlawful conduct, were unsustainable; and (iv) the foregoing, once revealed, was likely to subject Fulgent Genetics to significant financial and/or reputational harm.
​
On August 4, 2022, Fulgent Genetics released its second quarter 2022 financial results, disclosing, among other items, that the U.S. Securities and Exchange Commission (“SEC”) was conducting an investigation into certain of Fulgent Genetics’ reports filed with the SEC from 2018 through the first quarter of 2020.  The disclosure followed Fulgent Genetics’ receipt of a civil investigative demand issued by the U.S. Department of Justice related to its "investigation of allegations of medically unnecessary laboratory testing, improper billing for laboratory testing, and remuneration received or provided in violation of the Anti-Kickback Statute and the Stark Law."  On this news, Fulgent Genetics’ stock price fell by more than 17%, damaging investors who suffered losses in ​Fulgent Genetics stock.

​The Private Securities Litigation Reform Act of 1995 permits any investor who purchased and suffered losses in Fulgent Genetics stock to seek appointment as lead plaintiff in the Fulgent Genetics class action lawsuit. A lead plaintiff is generally the movant with the greatest financial interest in the relief sought by the putative class who is also typical and adequate of the putative class.  A lead plaintiff acts on behalf of all other class members in directing the class action lawsuit. The lead plaintiff can select a law firm of its choice to litigate the securities class action lawsuit.  An investor’s ability to share in any potential future recovery of the class action lawsuit is not dependent upon serving as lead plaintiff. If you suffered losses in Fulgent Genetics stock, and have further questions, contact Fulgent Genetics ​Stock Loss Lawyer Timothy L. Miles today who will fight to recover your damages.

A Fulgent Genetics Stock Loss Lawyer is well-versed in the complex laws that govern the securities industry and litigation. A Fulgent Genetics Stock Loss Lawyer focuses on representing individual investors or funds who have been the victims of fraud or who have disputes with investment professionals. Ordinary individual investors, including civil servants, teachers, nurses, and retirees, may need a securities lawyer. In most cases, if they have lost money due to mistakes, incompetence, or fraud by an investment professional. While FINRA, the SEC, and state securities regulators serve a vital role in protecting investors, they simply have too many individuals, firms, and market transactions to monitor to discovery every act of fraud or negligence. Individual investors should consult with a securities lawyer if they have lost money due to fraud or stockbroker misconduct, such as a Fulgent Genetics Stock Loss Lawyer who will work to recover the losses you sustained through a Fulgent Genetics Class Action lawsuit.

If you suffered losses in Fulgent Genetics contact Palantir stock loss lawyer Timothy L. Miles today about a Fulgent Genetics class action lawsuit, and see what a Fulgent Genetics Loss Lawyer can do for you. We take all cases on a contingency basis which means we do not get paid unless we win your case. 

​An Investor who suffered losses in Palantir stock has filed Palantir Class Action Lawsuit. The Palantir class action lawsuit – captioned Cupat v. Palantir Technologies Inc., No. 22-cv-02384 (D. Colo.) – charges Palantir Technologies Inc. (NYSE: PLTR) and certain of its top executives with violations of the Securities Exchange Act of 1934 and was brought on behalf of all persons and entities that purchased or otherwise acquired Palantir securities between November 9, 2021 and May 6, 2022
​
If you suffered losses in Palantir stock and wish to serve as lead plaintiff of the Palantir class action lawsuit, please provide your information here.  You can also contact Palantir Stock Loss Lawyer Timothy L. Miles by calling 855/846-6529 or via e-mail at tmiles@timmileslaw.com.  Lead plaintiff motions for the Palantir class action lawsuit must be filed with the court no later than November 14, 2022. If you suffered losses in Palantir stock and have questions, please contact Palantir Stock Loss Lawyer Timothy L. Miles today.

Palantir builds and deploys software platforms to assist the U.S. intelligence community in counterterrorism investigations and operations.  Palantir has consistently described sources of geopolitical instability and other disruptions – e.g., armed conflicts, economic crises, and the COVID-19 pandemic – as tailwinds for its business.  Palantir also invests in so-called “marketable securities” consisting of equity securities in publicly traded companies.
 
The Palantir class action lawsuit alleges that defendants failed to disclose that: (i) Palantir’s investments in marketable securities were having a significant negative impact on Palantir’s earnings per share (“EPS”) results; (ii) Palantir overstated the sustainability of its government segment’s growth and revenues; (iii) Palantir was experiencing a significant slowdown in revenue growth, particularly among its government customers, despite ongoing global conflicts and market disruptions; and (iv) as a result, Palantir was likely to miss consensus estimates for its first quarter 2022 (“Q1”) EPS and second quarter 2022 (“Q2”) sales outlook.
​
On May 9, 2022, Palantir issued a press release announcing its Q1 financial results and guidance for Q2.  For Q1, Palantir announced adjusted EPS of $0.02, compared to analyst estimates of $0.04 per share, noting on a conference call that the “[f]irst quarter adjusted [EPS of] $0.02 . . . includes a negative $0.02 impact driven primarily by unrealized losses on marketable securities.”  Palantir also disclosed that government revenue grew by only 16% year-over-year for Q1, representing a significant slowdown in revenue growth compared to prior quarters, and that, for Q2, Palantir expected $470 million in sales, compared to estimates of $483.76 million.  Palantir’s significant decline in revenue growth, particularly from its government customers, surprised investors, especially given the ongoing geopolitical instability and other disruptions caused by, among other things, the ongoing COVID-19 pandemic and Russo-Ukrainian War – that is, precisely the type of destabilizing conditions that Palantir had previously touted as tailwinds for its business. 

​On this news, Palantir’s stock price fell by more than 21%, damaging investors who suffered losses in Palantir stock.

​The Private Securities Litigation Reform Act of 1995 permits any investor who purchased and suffered losses in Palantir stock to seek appointment as lead plaintiff in the Palantir class action lawsuit. A lead plaintiff is generally the movant with the greatest financial interest in the relief sought by the putative class who is also typical and adequate of the putative class.  A lead plaintiff acts on behalf of all other class members in directing the class action lawsuit. The lead plaintiff can select a law firm of its choice to litigate the securities class action lawsuit.  An investor’s ability to share in any potential future recovery of the class action lawsuit is not dependent upon serving as lead plaintiff. If you suffered losses in Palantir stock, and have further questions, contact Palantir ​Stock Loss Lawyer Timothy L. Miles today who will fight to recover your damages.

​A Palantir Stock Loss Lawyer is well-versed in the complex laws that govern the securities industry and litigation. A Palantir Stock Loss Lawyer focuses on representing individual investors or funds who have been the victims of fraud or who have disputes with investment professionals. Ordinary individual investors, including civil servants, teachers, nurses, and retirees, may need a securities lawyer. In most cases, if they have lost money due to mistakes, incompetence, or fraud by an investment professional. While FINRA, the SEC, and state securities regulators serve a vital role in protecting investors, they simply have too many individuals, firms, and market transactions to monitor to discovery every act of fraud or negligence. Individual investors should consult with a securities lawyer if they have lost money due to fraud or stockbroker misconduct, such as a Palantir Stock Loss Lawyer who will work to recover the losses you sustained through a Palantir Class Action lawsuit.​

​If you suffered losses in Palantir stock, contact Palantir stock loss lawyer Timothy L. Miles today about a Palantir class action lawsuit, and see what a Palantir Stock Loss Lawyer can do for you.  We take all cases on a contingency basis which means we do not get paid unless we win your case.

The Twitter class action lawsuit seeks to represent purchasers or acquirers of Twitter, Inc. (NYSE: TWTR) publicly traded securities between August 3, 2020 and August 23, 2022, inclusive (the “Class Period”).  The Twitter class action lawsuit – captioned Baker v. Twitter, Inc., No. 22-cv-06525 (C.D. Cal.) – charges Twitter and certain of its top executives with violations of the Securities Exchange Act of 1934.
​
​If you suffered losses in Twitter stock and wish to serve as lead plaintiff of the Twitter class action lawsuit, please provide your information below.  You can also contact Twitter Stock Loss Lawyer Timothy L. Miles by calling 855/846-6529 or via e-mail at tmiles@timmileslaw.com.  Lead plaintiff motions for the Twitter class action lawsuit must be filed with the court no later than November 14, 2022. If you suffered losses in Twitter stock and have questions, please contact Twitter Stock Loss Lawyer Timothy L. Miles today.

In 2010, the Federal Trade Commission (“FTC”) filed a complaint against Twitter for mishandling users’ private information and the issue of too many employees having access to Twitter’s central controls.  On March 11, 2011, the FTC agreed to a settlement with Twitter and, as part of the settlement, Twitter agreed it would be “barred for 20 years from misleading consumers about the extent to which it protects the security, privacy, and confidentiality of nonpublic consumer information, including the measures it takes to prevent unauthorized access to nonpublic information and honor the privacy choices made by consumers.”

However, as the Twitter class action lawsuit alleges, defendants failed to disclose that: (i) Twitter knew about security concerns on their platform; (ii) Twitter actively worked to hide the security concerns from their Board of Directors, the investing public, and regulators; (iii) contrary to representations in U.S. Securities and Exchange Commission (“SEC”) filings, Twitter did not take steps to improve security; and (iv) Twitter’s active refusal to address security issues increased the risk of loss of public goodwill.

On August 23, 2022, CNN published an article titled “Ex-Twitter exec blows the whistle, alleging reckless and negligent cybersecurity policies,” reporting that “Twitter has major security problems that pose a threat to its own users’ personal information, to [Twitter] shareholders, to national security, and to democracy, according to an explosive whistleblower disclosure obtained exclusively by CNN and The Washington Post.”  The article further revealed that “[t]he whistleblower, who has agreed to be publicly identified, is Peiter ‘Mudge’ Zatko, who was previously [Twitter’s] head of security, reporting directly to the CEO.”  Specifically, “Zatko further alleges that Twitter’s leadership has misled its own board and government regulators about its security vulnerabilities, including some that could allegedly open the door to foreign spying or manipulation, hacking and disinformation campaigns.”
​
​On this news, Twitter’s stock price fell by approximately 7%, damaging investors who suffered losses in Twitter stock.

​The Private Securities Litigation Reform Act of 1995 permits any investor who purchased and suffered losses in Twitter stock to seek appointment as lead plaintiff in the Twitter class action lawsuit. A lead plaintiff is generally the movant with the greatest financial interest in the relief sought by the putative class who is also typical and adequate of the putative class.  A lead plaintiff acts on behalf of all other class members in directing the class action lawsuit. The lead plaintiff can select a law firm of its choice to litigate the class action lawsuit.  An investor’s ability to share in any potential future recovery of the class action lawsuit is not dependent upon serving as lead plaintiff. If you suffered losses in Twitter stock, and have further questions, contact Twitter ​Stock Loss Lawyer Timothy L. Miles today.

​A Twitter Stock Loss Lawyer is well-versed in the complex laws that govern the securities industry and litigation. A Twitter Stock Loss Lawyer focuses on representing individual investors or funds who have been the victims of fraud or who have disputes with investment professionals. Ordinary individual investors, including civil servants, teachers, nurses, and retirees, may need a securities lawyer. In most cases, if they have lost money due to mistakes, incompetence, or fraud by an investment professional. While FINRA, the SEC, and state securities regulators serve a vital role in protecting investors, they simply have too many individuals, firms, and market transactions to monitor to discovery every act of fraud or negligence. Individual investors should consult with a securities lawyer if they have lost money due to fraud or stockbroker misconduct, such as a Twitter Stock Loss Lawyer who will work to recover the losses you sustained through a Twitter Class Action lawsuit.​

​​If you suffered losses in Twitter stock, contact Twitter stock loss lawyer Timothy L. Miles today about a Twitter class action lawsuit, and see what a Twitter Stock Loss Lawyer can do for you.

​The Kohl’s class action lawsuit seeks to represent purchasers or acquirers of Kohl’s Corporation (NYSE: KSS) securities between October 20, 2020 and May 19, 2022, inclusive (the “Class Period”).  The Kohl’s class action lawsuit – captioned Shanaphy v. Kohl’s Corporation, No. 22-cv-01016 (E.D. Wis.) – charges Kohl’s as well as certain of its top executives and directors with violations of the Securities Exchange Act of 1934.
​
If you suffered losses in Kohl’s stock and wish to serve as lead plaintiff of the Kohl’s class action lawsuit, please provide your information below.  You can also contact Kohl’s Stock Loss Lawyer Timothy L. Miles by calling 855/846-6529 or via e-mail at tmiles@timmileslaw.com.  Lead plaintiff motions for the Kohl’s class action lawsuit must be filed with the court no later than November 1, 2022. If you suffered losses in Kohl’s stock and have questions, please contact Kohl’s Stock Loss Lawyer Timothy L. Miles today.

​In October 2020, Kohl’s announced that it had entered into a new strategic framework to “drive top-line growth,” “expand operating margin,” and become “the most trusted retailer of choice for the active and casual lifestyle” (the “Strategic Plan”).  In announcing the Strategic Plan, Kohl’s touted its purportedly strong foundation of customers, industry-leading loyalty and charge card programs, high volume of stores, and large and growing digital business.
 
The Kohl’s class action lawsuit alleges that defendants failed to disclose that: (i) Kohl’s Strategic Plan was not well tailored to achieving Kohl’s stated goals; (ii) the defendants had likewise overstated Kohl’s success in executing its Strategic Plan; (iii) Kohl’s had deficient disclosure controls and procedures, internal control over financial reporting, and corporate governance mechanisms; (iv) as a result, Kohl’s Board of Directors was able to and did withhold material information from shareholders about the state of Kohl’s in the lead-up to Kohl’s annual meeting; and (v) all the foregoing, once revealed, was likely to have a material negative impact on Kohl’s financial condition and reputation.
​
On May 19, 2022, Kohl’s announced its first quarter of 2022 results, reporting, among other items, a net sales figure expected to grow up to only 1% (compared to Wall Street consensus growth of 1.94%), earnings per share of $0.11 (missing estimates by $0.59), a revenue figure which only barely edged expectations, and Kohl’s decision to cut its full year earnings forecast.  These results were at odds with defendants’ representations regarding the successful execution of Kohl’s Strategic Plan, which was purportedly poised to drive top-line growth and position Kohl’s for long-term success.
 
Then, on May 20, 2022, Macellum Advisors GP, LLC, “a long-term holder of nearly 5% of the outstanding common shares of Kohl’s,” issued a statement addressing “[t]his quarter’s extremely disappointing results,” which Macellum attributed to a “flawed strategic plan and an inability to execute.”  Macellum also stated that “the current Board appears to have withheld material information from shareholders about the state of Kohl’s in the lead-up to this year’s pivotal annual meeting,” which “suggests to us a clear breach of fiduciary duty.”  On this news, Kohl’s stock price fell by nearly 13%, damaging investors who suffered losses in Kohl's stock.

​The Private Securities Litigation Reform Act of 1995 permits any investor who purchased and suffered losses in Kohl’s stock to seek appointment as lead plaintiff in the Kohl’s​ class action lawsuit. A lead plaintiff is generally the movant with the greatest financial interest in the relief sought by the putative class who is also typical and adequate of the putative class. 

​A lead plaintiff acts on behalf of all other class members in directing the class action lawsuit.  The lead plaintiff can select a law firm of its choice to litigate the class action lawsuit.  An investor’s ability to share in any potential future recovery of the class action lawsuit is not dependent upon serving as lead plaintiff. If you suffered losses in Kohl’s stock, and have further questions, contact Kohl’s Stock Loss Lawyer Timothy L. Miles today.

A Kohl’s​ Stock Loss Lawyer is well-versed in the complex laws that govern the securities industry and litigation. A Kohl’s Stock Loss Lawyer focuses on representing individual investors or funds who have been the victims of fraud or who have disputes with investment professionals. Ordinary individual investors, including civil servants, teachers, nurses, and retirees, may need a securities lawyer. In most cases, if they have lost money due to mistakes, incompetence, or fraud by an investment professional.

​While FINRA, the SEC, and state securities regulators serve a vital role in protecting investors, they simply have too many individuals, firms, and market transactions to monitor to discovery every act of fraud or negligence. Individual investors should consult with a securities lawyer if they have lost money due to fraud or stockbroker misconduct, such as a Kohl’s Stock Loss Lawyer who will work to recover the losses you sustained through a Kohl’s Class Action lawsuit.​

​If you suffered losses in Kohl’s stock, contact Kohl’s stock loss lawyer Timothy L. Miles today about a Kohl’s class action lawsuit, and see what an Kohl’s​ Stock Loss Lawyer can do for you.

​The LifeStance Health class action lawsuit seeks to represent purchasers of LifeStance Health Group, Inc. (NASDAQ: LFST) common stock issued in connection with LifeStance Health’s June 10, 2021 initial public stock offering (the “IPO”).  Captioned Nayani v. LifeStance Health Group, Inc., No. 22-cv-06833 (S.D.N.Y.) – the LifeStance Health class action lawsuit charges LifeStance Health, certain of its top executives and directors, as well as the IPO’s underwriters with violations of the Securities Act of 1933.
Additionally, read on to learn about the Firm’s investigation of the LifeStance Health Board.

LifeStance Health is one of the nation’s largest providers of virtual and in-person outpatient mental health care.  LifeStance Health benefitted from the state and local lockdown orders necessitated by the COVID-19 pandemic starting in the spring of 2020.  But by December 2020, several COVID-19 vaccines were being approved and administered, meaning LifeStance Health’s access to clients seeking virtual mental health services would significantly decline while demand for in-person services would increase.  LifeStance Health conducted its IPO on June 10, 2021, selling 46 million shares at $18.00 per share, raising $828 million in gross proceeds.
 
However, as the LifeStance Health class action lawsuit alleges, the IPO’s registration statement failed to disclose the following material facts: (i) that the number of virtual visits clients were undertaking utilizing LifeStance Health was decreasing as the COVID-19 lockdowns were being lifted, thereby flatlining LifeStance Health’s out-patient/virtual revenue growth; (ii) that the percentage of in-person visits clients were undertaking utilizing LifeStance Health was increasing as the COVID-19 lockdowns were being lifted, thereby causing LifeStance Health’s operating expenses to increase substantially; (iii) that LifeStance Health had lost a large number of physicians due to burn-out and, as a result, its physician retention rate had fallen significantly below the 87% highlighted in the IPO’s registration statement and LifeStance Health had been expending additional costs to onboard new physicians who were less productive than the outgoing physicians they were replacing; and (iv) as a result, LifeStance Health’s business metrics and financial prospects were not as strong as the IPO’s registration statement represented.
 
At the time of the LifeStance Health class action lawsuit’s filing, LifeStance Health common stock traded in a range of $4.77-$7.70, a reduction of upwards of 73% from the price the shares were sold at in the IPO, as investors suffered losses in LifeStance Health.

​​The investigation of the LifeStance Health board focuses on whether the board of directors of LifeStance Health have breached their fiduciary duties to the company in light of the serious allegations raised in the LifeStance Health class action lawsuit filed against the Company and the resulting loss of market capitalization, among others.  The firm urges long-term stockholders of LifeStance Health to call LifeStance Health Stock Loss Lawyer Timothy L. Miles today or simply submit the form at the bottom of the link if you have questions about the investigation of the LifeStance Health Board which remains ongoing.

​​If you are a long-term stockholder of LifeStance Health, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact LifeStance Health Stock Loss Lawyer, Timothy L. Miles, by email at tmiles@timmileslaw.com, or telephone at (858) Tim-M-Law, or by filling out the contact form at the bottom of the link and someone will promptly call you back. There is no cost or obligation to you, so go ahead and call and see what a LifeStance Health Stock Loss Lawyer can do for you.

​The Co-Diagnostics class action lawsuit seeks to represent purchasers of Co-Diagnostics, Inc. (NASDAQ: CODX) publicly traded securities between May 12, 2022 and the close of the market on August 11, 2022 (4:00 p.m. ET), inclusive (the “Class Period”).  The Co-Diagnostics class action lawsuit – captioned Stadium Capital LLC v. Co-Diagnostics, Inc., No. 22-cv-06978 (S.D.N.Y.) – charges Co-Diagnostics and certain of its top executive officers with violations of the Securities Exchange Act of 1934.​​ 

​On April 6, 2020, Co-Diagnostics announced that it had received an Emergency Use Authorization for its Logix Smart™ COVID-19 detection test from the U.S. Food and Drug Administration, allowing it to commence sales of the test to laboratories certified by the Center for Medicare and Medicaid Services under the Clinical Laboratories Improvements Act to accept human samples for diagnostics testing throughout the United States.
 
The Co-Diagnostics class action lawsuit alleges that defendants failed to disclose that: (i) demand for its Logix Smart™ COVID-19 test had plummeted throughout the quarter ended June 30, 2022, and (ii) as a result, defendants’ positive statements about the demand for its Logix Smart™ COVID-19 test lacked a reasonable basis.
 
On August 11, 2022, Co-Diagnostics disclosed its financial results for the quarter ended June 30, 2022, in which Co-Diagnostics revealed revenue of $5.0 million for the quarter ended June 30, 2022, down from $27.4 million during the prior year period, a decline of almost 82%.  Co-Diagnostics primarily attributed the decrease to lower demand of the Logix Smart™ COVID-19 test.  On this news, the price of Co-Diagnostics common stock declined by more than 30%, damaging investors who suffered losses in Co-Diagnostics stock.

​The investigation of the Co-Diagnostics board focuses on whether the board of directors of Co-Diagnostics have breached their fiduciary duties to the company in light of the serious allegations raised in the Coinbase class action lawsuit filed against the Company.  The firm urges long-term stockholders of Coinbase to call Co-Diagnostics Stock Loss Lawyer Timothy L. Miles today or simply submit the form at the bottom of the link if you have questions about the investigation of the Coinbase Board which remains ongoing.

​If you are a long-term stockholder of Co-Diagnostics, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Co-Diagnostics Stock Loss Lawyer, Timothy L. Miles, by email at tmiles@timmileslaw.com, or telephone at (858) Tim-M-Law, or by filling out the contact form at the bottom of the link and someone will promptly call you back. There is no cost or obligation to you, so go ahead and call and see what a Co-Diagnostics Stock Loss Lawyer can do for you.

The Coinbase class action lawsuit seeks to represent purchasers or acquirers of Coinbase Global, Inc. (NASDAQ: COIN) securities between April 14, 2021 and July 26, 2022, inclusive (the “Class Period”).  The Coinbase class action lawsuit – captioned Patel v. Coinbase Global, Inc., No. 22-cv-04915 (D.N.J.) – charges Coinbase and certain of its top executive officers with violations of the Securities Exchange Act of 1934.

​The Coinbase class action lawsuit alleges that, throughout the Class Period, defendants made false and misleading statements and failed to disclose that: (i) Coinbase custodially held crypto assets on behalf of its customers, which assets Coinbase knew or recklessly disregarded could qualify as the property of a bankruptcy estate, making those assets potentially subject to bankruptcy proceedings in which Coinbase’s customers would be treated as Coinbase’s general unsecured creditors; (ii) Coinbase allowed Americans to trade digital assets that Coinbase knew or recklessly disregarded should have been registered as securities with the U.S. Securities and Exchange Commission (“SEC”); and (iii) the foregoing conduct subjected Coinbase to a heightened risk of regulatory and governmental scrutiny and enforcement action.
 
On May 10, 2022, Coinbase disclosed that: “Because custodially held crypto assets may be considered to be the property of a bankruptcy estate, in the event of a bankruptcy, the crypto assets we hold in custody on behalf of our customers could be subject to bankruptcy proceedings and such customers could be treated as our general unsecured creditors.”  Following this disclosure, the price of Coinbase Class A common stock fell by more than 26%.
​
Then, on July 25, 2022, Bloomberg reported that Coinbase is facing an SEC probe into whether it improperly let Americans trade digital assets that should have been registered as securities.  On this news, the price of Coinbase Class A common stock fell by an additional 21%, further damaging investors who suffered losses in Coinbase stock. 

​The investigation of the Coinbase board focuses on whether the board of directors of Coinbase have breached their fiduciary duties to the company in light of the serious allegations raised in the Coinbase class action lawsuit filed against the Company.  The firm urges long-term stockholders of Coinbase to call an Coinbase Stock Loss Lawyer Timothy L. Miles today or simply submit the form at the bottom of the link if you have questions about the investigation of the Coinbase Board.

​If you are a long-term stockholder of Coinbase, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Coinbase Stock Loss Lawyer, Timothy L. Miles, by email at tmiles@timmileslaw.com, or telephone at (858) Tim-M-Law, or by filling out the contact form at the bottom of the link and someone will promptly call you back. There is no cost or obligation to you, so go ahead and call and see what an Coinbase Stock Loss Lawyer can do for you.
 

​The Outset Medical class action lawsuit seeks to represent purchasers or acquirers of Outset Medical, Inc. (NASDAQ: OM) common stock between September 15, 2020 and June 13, 2022, inclusive (the “Class Period”).  The Outset Medical class action lawsuit – captioned Plymouth County Retirement Association v. Outset Medical, Inc., No. 22-cv-04016 (N.D. Cal.) – charges Outset Medical and certain of its top executive officers with violations of the Securities Exchange Act of 1934 and is brought on behalf of investors who purchased Outset Medical stock during the Class Period.

​Outset Medical’s flagship product is the Tablo Hemodialysis System, a dialysis machine that purifies tap water and then artificially purifies and removes toxins from the blood of patients suffering from kidney failure.
 
Throughout the Class Period, Outset Medical touted that Tablo can “serve as a dialysis clinic on wheels” that had been “cleared by the [U.S.] Food and Drug Administration (FDA) for use in the hospital, clinic or home setting.”  However, devices used by non-professionals outside of a clinical setting and that can present serious health consequences like Tablo are subject to heightened scrutiny by the FDA, including post-market surveillance studies.  Thus, though cleared by the FDA for sale, Tablo for use in the home setting was subject to additional studies, the results of which could require additional applications for clearance and approvals.  And while performing further regulatory studies during the Class Period, Outset Medical assured investors that it was conducting the studies “in accordance with the FDA approved protocol,” which required an appropriate demonstration of “real-world” human testing given that the device would be used at home by non-professionals.
​
But as the Outset Medical class action lawsuit alleges, undisclosed to investors, Outset Medical continuously made significant changes to Tablo for use in the home setting.  The nature of these undisclosed changes: (i) made it likely that the FDA would order Outset Medical to cease all marketing and selling of Tablo for use in the home pending additional applications and approvals; and (ii) prevented Outset Medical from performing the requisite “real-world” human testing on a device cleared for sale, contrary to representations to investors.
 
On May 4, 2022, Tablo Medical announced disappointing results for the first quarter of 2022, which analysts attributed, among other things, to the untested nature of Tablo in the home setting.  On this news, the price of Outset Medical common stock declined more than 40% over the three trading days that followed.
 
Then, on June 13, 2022, Outset Medical announced that the FDA had forced it to hold all shipments of Tablo for use in the home until Tablo received proper regulatory clearance.  During a “Business Update” conference call held that day with analysts, Outset Medical CEO Leslie Trigg acknowledged the “ship hold” had already been in place for weeks before investors were provided this material information.  Importantly, CEO Trigg disclosed for the first time that, rather than conducting studies using “real-world data” gathered in the “home environment” as Outset Medical previously stated was required by the FDA, in reality, Outset Medical had “run with a protocol that involves a simulated use environment at a human factors lab.”  On this news, the price of Outset Medical stock fell an additional 34%, further damaging investors who suffered losses in Outset Medical stock. 

​The investigation of the Outset Medical board focuses on whether the board of directors of Outset Medical have breached their fiduciary duties to the company in light of the serious allegations raised in the Outset Medical class action lawsuit filed against the Company.  The firm urges long-term stockholders of Outset Medical to call an Outset Medical Stock Loss Lawyer Timothy L. Miles today or simply submit the form at the bottom of the link if you have questions about the investigation of the Outset Medical Board.

​If you are a long-term stockholder of Outset Medical, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Outset Medical Stock Loss Lawyer, Timothy L. Miles, by email at tmiles@timmileslaw.com, or telephone at (858) Tim-MLaw, or by filling out the contact form at the bottom of the link and someone will promptly call you back. There is no cost or obligation to you, so go ahead and call and see what an Outset Medical Lawyer can do for you.

​The Yext class action lawsuit seeks to represent purchasers or acquirers of Yext, Inc. (NYSE: YEXT) securities between March 4, 2021 and March 8, 2022, inclusive (the “Class Period”).  The Yext class action lawsuit – captioned Menzione v. Yext, Inc., No. 22-cv-05127 (S.D.N.Y.) – charges Yext and certain of its top executive officers with violations of the Securities Exchange Act of 1934. Read on to learn more including the Firm’s investigation of the Board for possible breaches of fiduciary duty and other violations.

​​​ Yext operates Yext platform, a cloud-based platform that allows its customers to, among other things, provide answers to consumer questions, control facts about their businesses and the content of their landing pages, and manage their consumer reviews.  As COVID-19 resurged throughout 2021, Yext consistently assured investors that pandemic-related impacts on Yext’s business were limited as Yext adapted to lockdowns and improved efficiencies in its sales and other operations.
 
The Yext class action lawsuit alleges that, throughout the Class Period, defendants made false and misleading statements and failed to disclose that: (i) Yext’s revenue and earnings were significantly deteriorating because of, among other things, poor sales execution and performance, as well as COVID-19 related disruptions; (ii) accordingly, Yext was unlikely to meet consensus estimates for its full year fiscal 2022 financial results and fiscal 2023 outlook; and (iii) as a result, Yext’s public statements were materially false and misleading at all relevant times.
​
On March 8, 2022, Yext reported fourth quarter of fiscal 2022 revenue of $100.9 million, falling short of consensus estimates by $140,000; first quarter of fiscal 2023 revenue outlook of $96.3 million to $97.3 million, versus consensus estimates of $103.79 million; first quarter of fiscal 2023 non-Generally Accepted Accounting Principles (“GAAP”) net loss per share outlook of $0.08 to $0.07, versus consensus estimates of $0.05; full year fiscal 2023 revenue outlook of $403.3 million to $407.3 million, versus consensus estimates of $444.71 million; and full year fiscal 2023 non-GAAP net loss per share outlook of $0.19 to $0.17, versus consensus estimates of $0.09.  Yext further disclosed the departure of its CEO and CFO.  On this news, Yext’s stock price fell more than 9%, damaging investors who suffered losses in Yext stock. If you have further questions about the Yext class action lawsuit, please contact ​Yext Stock Loss Lawyer Timothy L. Miles today.

​The investigation of the Yext board focuses on whether the board of directors of Yext have breached their fiduciary duties to the company in light of the serious allegations raised in the Yext class action lawsuit filed against the Company.  The firm urges long-term stockholders of Yext to call a Yext Stock Loss Lawyer Timothy L. Miles today or simply submit the form at the bottom of the link if you have questions about the investigation of the Yext Board.

​If you are a long-term stockholder of Yext, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Yext Stock Loss Lawyer, Timothy L. Miles, by email at tmiles@timmileslaw.com, or telephone at (858) Tim-MLaw, or by filling out the contact form at the bottom of the link and someone will promptly call you back. There is no cost or obligation to you, so go ahead and call and see what a Yext Lawyer can do for you.